These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20368213)

  • 1. Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes.
    Rubin CJ; Viraswami-Appanna K; Fiedorek FT
    Diab Vasc Dis Res; 2009 Jul; 6(3):205-15. PubMed ID: 20368213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coadministration of muraglitazar plus glyburide: improvement of glycaemic and lipid profiles in patients with type 2 diabetes.
    Rubin CJ; De Pril V; Fiedorek FT
    Diab Vasc Dis Res; 2009 Apr; 6(2):120-32. PubMed ID: 20368202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
    Buse JB; Rubin CJ; Frederich R; Viraswami-Appanna K; Lin KC; Montoro R; Shockey G; Davidson JA
    Clin Ther; 2005 Aug; 27(8):1181-95. PubMed ID: 16199244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride.
    Rubin CJ; Ledeine JM; Fiedorek FT
    Diab Vasc Dis Res; 2008 Sep; 5(3):168-76. PubMed ID: 18777489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
    Henry RR; Lincoff AM; Mudaliar S; Rabbia M; Chognot C; Herz M
    Lancet; 2009 Jul; 374(9684):126-35. PubMed ID: 19515415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
    Nissen SE; Wolski K; Topol EJ
    JAMA; 2005 Nov; 294(20):2581-6. PubMed ID: 16239637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
    Herz M; Johns D; Reviriego J; Grossman LD; Godin C; Duran S; Hawkins F; Lochnan H; Escobar-Jiménez F; Hardin PA; Konkoy CS; Tan MH
    Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy.
    Henriksen K; Byrjalsen I; Qvist P; Beck-Nielsen H; Hansen G; Riis BJ; Perrild H; Svendsen OL; Gram J; Karsdal MA; Christiansen C;
    Diabetes Metab Res Rev; 2011 May; 27(4):392-401. PubMed ID: 21328517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial.
    Kaku K
    Curr Med Res Opin; 2009 May; 25(5):1111-9. PubMed ID: 19309251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events related to muraglitazar use in diabetes.
    Parra D; Beckey C; Thomas T
    JAMA; 2006 May; 295(17):1997-8; author reply 1998. PubMed ID: 16670403
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes.
    Kong AP; Yamasaki A; Ozaki R; Saito H; Asami T; Ohwada S; Ko GT; Wong CK; Leung GT; Lee KF; Yeung CY; Chan JC
    Diabetes Obes Metab; 2011 Sep; 13(9):806-13. PubMed ID: 21492364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy.
    Berhanu P; Perez A; Yu S
    Diabetes Obes Metab; 2007 Jul; 9(4):512-20. PubMed ID: 17587394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, phase III evaluation of the efficacy and safety of a new fixed-dose pioglitazone/glimepiride combination tablet in Japanese patients with type 2 diabetes.
    Hiroi S; Sugiura K; Matsuno K; Hirayama M; Kuriyama K; Kaku K; Kawakami K
    Diabetes Technol Ther; 2013 Feb; 15(2):158-65. PubMed ID: 23289434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus.
    Rajagopalan R; Perez A; Ye Z; Khan M; Murray FT
    Drugs Aging; 2004; 21(4):259-71. PubMed ID: 15012171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events related to muraglitazar use in diabetes.
    Najman DM
    JAMA; 2006 May; 295(17):1997; author reply 1998. PubMed ID: 16670404
    [No Abstract]   [Full Text] [Related]  

  • 18. A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes.
    Truitt KE; Goldberg RB; Rosenstock J; Chou HS; Merante D; Triscari J; Wang AC
    Curr Med Res Opin; 2010 Jun; 26(6):1321-31. PubMed ID: 20370378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dual peroxisome proliferator-activated receptor alpha/gamma activator muraglitazar prevents the natural progression of diabetes in db/db mice.
    Tozzo E; Ponticiello R; Swartz J; Farrelly D; Zebo R; Welzel G; Egan D; Kunselman L; Peters A; Gu L; French M; Chen S; Devasthale P; Janovitz E; Staal A; Harrity T; Belder R; Cheng PT; Whaley J; Taylor S; Hariharan N
    J Pharmacol Exp Ther; 2007 Apr; 321(1):107-15. PubMed ID: 17259449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study.
    Davidson JA; Perez A; Zhang J;
    Diabetes Obes Metab; 2006 Mar; 8(2):164-74. PubMed ID: 16448520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.